ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer

NCT01580735 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small-cell Lung Cancer

Interventions

DRUG: ARQ 197

Sponsor

Kyowa Kirin Co., Ltd.